Ormeloxifene

From WikiMD's WELLNESSPEDIA

Chemical structure of Ormeloxifene

Ormeloxifene, also known as centchroman, is a selective estrogen receptor modulator (SERM) used primarily as a contraceptive. It is a non-steroidal compound that exhibits both estrogenic and anti-estrogenic effects depending on the target tissue. Ormeloxifene is notable for its use in India as a weekly oral contraceptive.

Mechanism of Action[edit]

Ormeloxifene acts by modulating the estrogen receptors in various tissues. In the endometrium, it exerts an anti-estrogenic effect, preventing the proliferation of the endometrial lining, which is crucial for implantation of a fertilized egg. In the breast, it has a weak estrogenic effect, which may contribute to its potential use in breast cancer prevention.

Clinical Uses[edit]

Ormeloxifene is primarily used as a contraceptive. It is taken once a week, which is a unique dosing schedule compared to other oral contraceptives. Besides contraception, it is also used in the management of dysfunctional uterine bleeding and has been studied for its potential benefits in osteoporosis and breast cancer prevention.

Side Effects[edit]

Common side effects of Ormeloxifene include nausea, headache, and dizziness. Some users may experience changes in menstrual patterns, such as delayed periods or spotting. Long-term use has not been associated with significant adverse effects on bone mineral density.

Pharmacokinetics[edit]

Ormeloxifene is well absorbed after oral administration. It has a long half-life, which allows for its weekly dosing schedule. The drug is metabolized in the liver and excreted primarily in the feces.

History and Development[edit]

Ormeloxifene was developed in India and has been available since the early 1990s. It was initially marketed under the brand name "Saheli" and has been part of the national family planning program in India. Its development was part of an effort to provide a safe, effective, and convenient contraceptive option.

Related Pages[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.